Next Article in Journal
Wnt Signaling in Renal Cell Carcinoma
Next Article in Special Issue
A Perspective of Immunotherapy for Prostate Cancer
Previous Article in Journal
RASSF1A Site-Specific Methylation Hotspots in Cancer and Correlation with RASSF1C and MOAP-1
Previous Article in Special Issue
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Article Menu

Export Article

Open AccessArticle
Cancers 2016, 8(6), 56; doi:10.3390/cancers8060056

Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer

1
Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
2
Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA
3
Shield Biotech, Inc., Cleveland, OH 44106, USA
4
Department of Anatomical and Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
These two authors contributed equally to this work.
Current Address: Department of Genomic Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
§
Current Address: Department of Anatomic Pathology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT 84112, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Vita Golubovskaya
Received: 26 March 2016 / Revised: 25 May 2016 / Accepted: 6 June 2016 / Published: 16 June 2016
(This article belongs to the Special Issue Cancer Immunotherapies)
View Full-Text   |   Download PDF [1479 KB, uploaded 16 June 2016]   |  

Abstract

We have proposed that safe and effective protection against the development of adult onset cancers may be achieved by vaccination against tissue-specific self-proteins that are “retired” from expression at immunogenic levels in normal tissues as we age, but are overexpressed in emerging tumors. α-Lactalbumin is an example of a “retired” self-protein because its expression in normal tissues is confined exclusively to the breast during late pregnancy and lactation, but is also expressed in the vast majority of human triple negative breast cancers (TNBC)—the most aggressive and lethal form of breast cancer and the predominant form that occurs in women at high genetic risk including those with mutated BRCA1 genes. In anticipation of upcoming clinical trials, here we provide preclinical data indicating that α-lactalbumin has the potential as a vaccine target for inducing safe and effective primary immunoprevention as well as immunotherapy against TNBC. View Full-Text
Keywords: triple negative breast cancer; immunoprevention; immunotherapy; cancer vaccine; α-lactalbumin triple negative breast cancer; immunoprevention; immunotherapy; cancer vaccine; α-lactalbumin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Tuohy, V.K.; Jaini, R.; Johnson, J.M.; Loya, M.G.; Wilk, D.; Downs-Kelly, E.; Mazumder, S. Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer. Cancers 2016, 8, 56.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top